OKYO Pharma Limited (NASDAQ:OKYO – Get Free Report) traded down 1% during trading on Wednesday . The company traded as low as $1.03 and last traded at $1.04. 12,750 shares changed hands during trading, a decline of 90% from the average session volume of 123,111 shares. The stock had previously closed at $1.05.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of OKYO Pharma in a research note on Thursday, October 24th.
Read Our Latest Report on OKYO
OKYO Pharma Price Performance
OKYO Pharma Company Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Recommended Stories
- Five stocks we like better than OKYO Pharma
- Why Are Stock Sectors Important to Successful Investing?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Roth IRA Calculator: Calculate Your Potential Returns
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
